Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-599626 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| BMS-599626 | DRUG | - |
Inclusion Criteria: * Signed written informed consent * Available for periodic follow-up * Life expectancy of at least 3 months * ECOG performance status score 0-1 * Histologic or cytologic diagnosis of a primary malignancy of breast, ovarian, bladder, gastric, non small cell lung or colon origin *...
BMS-599626 is an investigational small molecule being studied for the treatment of HER2 or EGFR expressing advanced solid malignancies. It is in Phase 1 clinical development for this oncology indication.
BMS-599626 targets HER2 and EGFR, which are proteins involved in the growth of certain solid tumors. By targeting these receptors, the drug is being evaluated for its potential to treat advanced solid malignancies that express HER2 or EGFR.
BMS-599626 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol BMY.
BMS-599626 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed.
BMS-599626 has one completed Phase 1 clinical trial, identified as NCT00207012. This trial enrolled 45 participants with HER2 or EGFR expressing advanced solid malignancies and was conducted in France and Spain.
No alternative names for BMS-599626 have been reported. It is identified by its developmental code name BMS-599626.